Faruqi & Faruqi Investigation: Dyax Corp.
Faruqi & Faruqi, LLP Announces the Investigation of Dyax Corp. (DYAX) Over the Proposed Sale of the Company to Shire plc.
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Dyax Corp. (“Dyax” or the “Company”) (NasdaqGM:DYAX) for potential breaches of fiduciary duties in connection with the sale of the Company to Shire plc. for approximately $5.4 billion.
The Company’s stockholders will only receive $37.30 in cash (plus $4.00 in cash per share upon clinical approval of DX-2930) for each share of Dyax common stock they own. However, the offer seems inadequate since Shire plc. expects approximately $2.0 billion in annual sales from DX-2930 if approved.
If you own common stock in Dyax and wish to obtain additional information and protect your investments free of charge, please contact Juan Monteverde, Esq. either via e-mail at firstname.lastname@example.org or by telephone at (877) 247-4292 or (212) 983-9330.